Scientific Reports · 2015 · 49 citations · 54 references
Life SciencesNeurobiologyNeuroscienceInflammationMolecular NeuroscienceNeurochemistryAlzheimer DiseaseEicosanoid BiosynthesisInflammatory SignalingNeurodegenerative DiseasesNeurodegenerative DisordersNeuroinflammationAlzheimer Disease ProgressionAmyloid Beta PeptidesAmyloid Beta PlaquesAmyloid PlaquesEicosanoid SignalingNeuroinflammation In Alzheimer DiseaseReceptorsTransgenic Mice
Senile plaques comprised of Aβ peptides are a hallmark of Alzheimer's disease (AD) brain, as are activated glia that release inflammatory molecules, including eicosanoids. Previous studies have demonstrated that amyloid precursor protein (APP) and Aβ levels can be increased through activation of thromboxane A2-prostanoid (TP) receptors on neurons. We demonstrate that TP receptor regulation of APP expression depends on Gαq-signaling and conventional protein kinase C isoforms. Importantly, we discovered that Gαq-linked prostaglandin E2 and leukotriene D4 receptors also regulate APP expression. Prostaglandin E2 and thromboxane A2, as well as total APP levels, were found to be elevated in the brains of aged 5XFAD transgenic mice harboring Aβ plaques and activated glia, suggesting that increased APP expression resulted from eicosanoid binding to Gαq-linked neuronal receptors. Notably, inhibition of eicosanoid synthesis significantly lowered brain APP protein levels in aged 5XFAD mice. These results provide new insights into potential AD therapeutic strategies.
54
Holly D. Oakley, Sarah L. Cole, Sreemathi Logan et al. · Journal of Neuroscience · 2006 · 3.6K citations · Full text
Virginia M.‐Y. Lee, Michel Goedert, John Q. Trojanowski · Annual Review of Neuroscience · 2001 · 2.4K citations
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Sascha Weggen, Jason L. Eriksen, Pritam Das et al. · Nature · 2001 · 1.4K citations